These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35226386)

  • 21. An exploration of aptamer internalization mechanisms and their applications in drug delivery.
    Wan LY; Yuan WF; Ai WB; Ai YW; Wang JJ; Chu LY; Zhang YQ; Wu JF
    Expert Opin Drug Deliv; 2019 Mar; 16(3):207-218. PubMed ID: 30691313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valency and affinity control of aptamer-conjugated nanoparticles for selective cancer cell targeting.
    Woythe L; Porciani D; Harzing T; van Veen S; Burke DH; Albertazzi L
    J Control Release; 2023 Mar; 355():228-237. PubMed ID: 36642253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer cell targeting using multiple aptamers conjugated on nanorods.
    Huang YF; Chang HT; Tan W
    Anal Chem; 2008 Feb; 80(3):567-72. PubMed ID: 18166023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivalent aptamer-modified tetrahedral DNA nanocage demonstrates high selectivity and safety for anti-tumor therapy.
    Han X; Jiang Y; Li S; Zhang Y; Ma X; Wu Z; Wu Z; Qi X
    Nanoscale; 2018 Dec; 11(1):339-347. PubMed ID: 30534748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered zwitterionic phosphorylcholine monolayers for elucidating multivalent binding kinetics of C-reactive protein.
    Goda T; Miyahara Y
    Acta Biomater; 2016 Aug; 40():46-53. PubMed ID: 26873368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insights into ligand binding to PreQ1 Riboswitch Aptamer from molecular dynamics simulations.
    Gong Z; Zhao Y; Chen C; Duan Y; Xiao Y
    PLoS One; 2014; 9(3):e92247. PubMed ID: 24663240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual aptamer-immobilized surfaces for improved affinity through multiple target binding in potentiometric thrombin biosensing.
    Goda T; Higashi D; Matsumoto A; Hoshi T; Sawaguchi T; Miyahara Y
    Biosens Bioelectron; 2015 Nov; 73():174-180. PubMed ID: 26067329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterizing the interaction between aptamers and human IgE by use of surface plasmon resonance.
    Wang J; Lv R; Xu J; Xu D; Chen H
    Anal Bioanal Chem; 2008 Feb; 390(4):1059-65. PubMed ID: 18084750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate-PNA and aptamer-PNA conjugates for the spatial screening of lectins and lectin assemblies.
    Scheibe C; Wedepohl S; Riese SB; Dernedde J; Seitz O
    Chembiochem; 2013 Jan; 14(2):236-50. PubMed ID: 23292704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multivalent Engineering of Exosomes with Activatable Aptamer Probes for Specific Regulation and Monitoring of Cell Targeting.
    Liu W; Huang Y; Li Z; Li L; Zhao Y; Li M
    Anal Chem; 2022 Mar; 94(9):3840-3848. PubMed ID: 35179366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural requirements of mono- and multivalent L-selectin blocking aptamers for enhanced receptor inhibition in vitro and in vivo.
    Riese SB; Buscher K; Enders S; Kuehne C; Tauber R; Dernedde J
    Nanomedicine; 2016 May; 12(4):901-908. PubMed ID: 26772426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA nanotriangle-scaffolded activatable aptamer probe with ultralow background and robust stability for cancer theranostics.
    Lei Y; Qiao Z; Tang J; He X; Shi H; Ye X; Yan L; He D; Wang K
    Theranostics; 2018; 8(15):4062-4071. PubMed ID: 30128036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping receptor density on live cells by using fluorescence correlation spectroscopy.
    Chen Y; Munteanu AC; Huang YF; Phillips J; Zhu Z; Mavros M; Tan W
    Chemistry; 2009; 15(21):5327-36. PubMed ID: 19360825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structured DNA Aptamer Interactions with Gold Nanoparticles.
    Mirau PA; Smith JE; Chávez JL; Hagen JA; Kelley-Loughnane N; Naik R
    Langmuir; 2018 Feb; 34(5):2139-2146. PubMed ID: 29283584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric aptamers in cancer cell-targeted drug delivery.
    Kanwar JR; Roy K; Kanwar RK
    Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing anti-PD-1 Immunotherapy by Nanomicelles Self-Assembled from Multivalent Aptamer Drug Conjugates.
    Geng Z; Wang L; Liu K; Liu J; Tan W
    Angew Chem Int Ed Engl; 2021 Jul; 60(28):15459-15465. PubMed ID: 33904236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Facile supermolecular aptamer inhibitors of L-selectin.
    Chang EK; Eckert MA; Ali MM; Riazifar H; Pone EJ; Liu L; Zhao W
    PLoS One; 2015; 10(3):e0123034. PubMed ID: 25826688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SELEX Modifications and Bioanalytical Techniques for Aptamer-Target Binding Characterization.
    Tan SY; Acquah C; Sidhu A; Ongkudon CM; Yon LS; Danquah MK
    Crit Rev Anal Chem; 2016 Nov; 46(6):521-37. PubMed ID: 26980177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer.
    Musumeci D; Montesarchio D
    Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.